Last updated on February 2018

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of two different schedules of administration of vemurafenib in combination with cobimetinib (continuous and intermittent) in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metastatic melanoma.

Clinical Study Identifier: NCT02583516

Contact Investigators or Research Sites near you

Start Over

Begoña Campos, MD, PhD

Hospital Universitario Lucus Augusti
Lugo, Spain